title: Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome.
abstract: OBJECTIVE
  To compare the effect of a gonadotropin releasing hormone (GnRH) analog plus 'add-back' oral contraceptive (OC) therapy with OC therapy alone on the clinical and hormonal parameters that are characteristic of polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective, randomized study.
  
  
  METHODS
  Thirty PCOS patients were randomly assigned to treatment with leuprolide acetate for depot suspension plus a combined monophasic OC (Group I) or to OC alone (Group II).
  
  
  METHODS
  Hormonal (luteinizing hormone (LH), follicle stimulating hormone (FSH), LH : FSH concentration ratio, estradiol, androstenedione, testosterone), clinical (Ferriman-Gallwey score), ultrasonographic (ovarian volume, number of subcapsular follicles, stromal score) and Doppler (uterine artery and ovarian intraparenchymal vessels' pulsatility index, ovarian stromal vascularization) parameters were evaluated during 6 months' therapy and 6 months' follow-up.
  
  
  RESULTS
  Significant changes in all the parameters analyzed occurred as a result of therapy and the changes were more marked in the group undergoing treatment with GnRH analog plus OC.
  
  
  CONCLUSIONS
  GnRH analog plus OC use has a more rapid and marked effect on the hormonal milieu as well as the ovarian architecture and vascularization in patients with PCOS than OC used alone. The former treatment may be a more efficient therapy for PCOS.
authors.affiliation: Department of Obstetrics and Gynecology, University of Modena, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Battaglia
authors.forename: A D
authors.initials: AD
authors.lastname: Genazzani
authors.forename: P G
authors.initials: PG
authors.lastname: Artini
authors.forename: M
authors.initials: M
authors.lastname: Salvatori
authors.forename: S
authors.initials: S
authors.lastname: Giulini
authors.forename: A
authors.initials: A
authors.lastname: Volpe
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D016014:Linear Models; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014463:Ultrasonography / Q000379:methods; D018615:Ultrasonography, Doppler, Color
chemical_list: D003276:Contraceptives, Oral; D003692:Delayed-Action Preparations; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide